The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 63.50
Bid: 62.00
Ask: 65.00
Change: 1.00 (1.60%)
Spread: 3.00 (4.839%)
Open: 62.50
High: 63.50
Low: 62.50
Prev. Close: 62.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Annual General Meeting

22 Jun 2015 13:19

RNS Number : 8379Q
NetScientific PLC
22 June 2015
 

 

 

 

NetScientific plc

 

Results of Annual General Meeting

 

 

London, UK - 22 June 2015 - NetScientific plc ("NetScientific" or "the Group", AIM: NSCI), the biomedical and healthcare technology group, announces that all resolutions proposed at today's Annual General Meeting have been duly passed.

 

As previously announced, Francois Martelet, the Company's new Chief Executive Officer, provided an update to shareholders, including his thoughts on the next steps for NetScientific. The Board intends to define clear value inflection points for the Company's leading assets and deliver value enhancing news flow across the Group. The presentation will be available on the Company's website later today.

 

As part of a review of the liquidity in the Company's shares, the Board also expressed its intention to consider a fundraising during the next 12 months to support the next stage of development in NetScientific's investment portfolio, with a focus on the Company's leading assets.

 

-Ends-

 

About NetScientific

 

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at www.netscientific.net. 

 

 

Contact Details

 

NetScientific

Peter Thoms, CFO

Tel: +44 (0)77 2055 5752

Investec

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

Instinctif Partners

Melanie Toyne-Sewell / Jayne Crook

Tel: +44 (0)20 7457 2020 Email: netscientific@instinctif.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGFTMTTMBBTBPA
Date   Source Headline
10th May 20249:12 amRNSPDS Biotech: Clinical trial meets study endpoints
15th Apr 20247:00 amRNSProAxsis secures c.£1.8mn investment
27th Mar 20241:34 pmRNSPDS Strategy Update and 2023 Financial Results
13th Mar 20247:00 amRNSBusiness Update
5th Feb 20247:00 amRNSExercise of Options and Issue of Shares
23rd Jan 20247:00 amRNSGlycotest secures $1 million investment
1st Dec 20237:00 amRNSDeepTech Recycling secures £1 million investment
14th Nov 20234:39 pmRNSPDS BioTechnology: Third Quarter Results
13th Nov 20237:00 amRNSDirector/PDMR Shareholding
9th Nov 20235:28 pmRNSPDS Biotech Announces Updated Survival Data
6th Nov 20237:00 amRNSVentive secures c.£900,000 investment
2nd Nov 20237:00 amRNSChange of Adviser
23rd Oct 20236:22 pmRNSPDS Preliminary Biomarker Study Results
13th Oct 20237:00 amRNSExercise of Options
3rd Oct 20234:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20233:21 pmRNSPDS: Interim 24-month survival rate of 74% update
3rd Oct 20237:00 amRNSPDS Biotech: new data on PDS0101
28th Sep 20237:00 amRNSInterim Results
13th Sep 20237:00 amRNSQ-Bot: £3.5 million investment to drive expansion
14th Aug 20235:55 pmRNSPDS Biotech: 2nd Quarter Results, Business Update
14th Aug 20235:51 pmRNSPDS Biotech: Submission of Phase 3 Protocol to FDA
3rd Jul 20237:00 amRNSGrant of Options, Issue of Shares, Director/PDMR
30th Jun 20237:00 amRNSDName-iT Holdings Limited Fundraising
29th Jun 202311:04 amRNSResult of AGM & Board Changes
22nd Jun 20237:00 amRNSVortex Fundraising
14th Jun 20233:31 pmRNSPDS Announces Achievement of Efficacy Threshold
7th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSNotice of AGM
31st May 20237:01 amRNSPreliminary Results for the year ended 31 Dec 2022
31st May 20237:00 amRNSBoard Changes
26th May 20239:39 amRNSPDS Biotech Announces Interim Data
24th May 20237:00 amRNSSofant and Inmarsat announce joint development
15th May 20233:16 pmRNSPDS Business Update and First Quarter Results
2nd May 20237:00 amRNSGlycotest, Inc. Fundraising
3rd Apr 20237:00 amRNSBusiness Update
30th Mar 20233:51 pmRNSPDS Update
28th Mar 20233:50 pmRNSPDS Business Update and 2022 Financial Results
28th Feb 20237:00 amRNSRelated party loan to ProAxsis Limited
27th Feb 20233:28 pmRNSPDS completes FDA meeting for triple combination
10th Feb 20232:05 pmRNSSecond Price Monitoring Extn
10th Feb 20232:00 pmRNSPrice Monitoring Extension
10th Feb 202311:05 amRNSSecond Price Monitoring Extn
10th Feb 202311:00 amRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSBoard Change
3rd Jan 20231:31 pmRNSPDS Announces Exclusive Global License Agreement
28th Dec 20223:05 pmRNSPDS Biotech: Median Overall Survival announcement
16th Dec 20227:00 amRNSPDS: HPV16 Head and Neck Cancer announcement
12th Dec 20222:00 pmRNSBoard Changes; Options; Co-Investment Agreement
29th Nov 20227:00 amRNSEMV C leads £4.2m round in 5G and SATCOM leader
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.